Complementary and Alternative Medicine for the Treatment of Depressive Disorders in Women

Psychiatric Clinics of North America

Volumn 33, Issue 2, 2010, Pages 441-463

  Deligiannidis, Kristina M ^a   Freeman, Marlene P ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acupuncture; Complementary alternative treatment; Depression; Omega 3 fatty acids; S Adenosylmethionine; St John's wort; Women

Indexed keywords

ALPHA TOCOPHEROL; DOCOSAHEXAENOIC ACID; FLUOXETINE; FOLIC ACID; GAMMA LINOLENIC ACID; HERBACEOUS AGENT; HORMONE; ICOSAPENTAENOIC ACID; IMIPRAMINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANTEPARTUM DEPRESSION; ANXIETY DISORDER; BIRTH DEFECT; BRIGHT LIGHT THERAPY; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; DEPRESSION; DIETARY INTAKE; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; HYPERICUM PERFORATUM; IRRITABILITY; KINESIOTHERAPY; LUTEAL PHASE; MAJOR DEPRESSION; MANIA; MENSTRUAL CYCLE; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PUERPERAL DEPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITEX AGNUS CASTUS;

ACUPUNCTURE THERAPY; ADULT; COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; EXERCISE THERAPY; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERICUM; PHOTOTHERAPY; PHYTOTHERAPY; PLANT PREPARATIONS; S-ADENOSYLMETHIONINE; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77951479113     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.01.002     Document Type: Review

References (181)

1. Cohen L.S., Soares C.N., Otto M.W., et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002, 70(2):125-132.
2. Rivera-Tovar A.D., Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990, 147(12):1634-1636.
3. Sternfeld B., Swindle R., Chawla A., et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002, 99(6):1014-1024.
4. Steiner M., Macdougall M., Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003, 6(3):203-209.
5. Wittchen H.U., Becker E., Lieb R., et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002, 32(1):119-132.
6. Kraemer G.R., Kraemer R.R. Premenstrual syndrome: diagnosis and treatment experiences. J Womens Health 1998, 7(7):893-907.
7. Regier D.A., Boyd J.H., Burke J.D., et al. One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch Gen Psychiatry 1988, 45(11):977-986.
8. Blazer D.G., Kessler R.C., McGonagle K.A., et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994, 151(7):979-986.
9. Llewellyn A.M., Stowe Z.N., Nemeroff C.B. Depression during pregnancy and the puerperium. J Clin Psychiatry 1997, 58(Suppl 15):26-32.
10. Warner R., Appleby L., Whitton A., et al. Demographic and obstetric risk factors for postnatal psychiatric morbidity. Br J Psychiatry 1996, 168(5):607-611.
11. Cox J.L., Murray D., Chapman G. A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry 1993, 163:27-31.
12. O'Hara M.W., Gorman L.L., Wright E.J. Description and evaluation of the Iowa Depression Awareness, Recognition, and Treatment Program. Am J Psychiatry 1996, 153(5):645-649.
13. Bennett H.A., Einarson A., Taddio A., et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004, 103(4):698-709.
14. Dietz P.M., Williams S.B., Callaghan W.M., et al. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007, 164(10):1515-1520.
15. Reck C., Stehle E., Reinig K., et al. Maternity blues as a predictor of DSM-IV depression and anxiety disorders in the first three months postpartum. J Affect Disord 2009, 113(1-2):77-87.
16. Vesga-Lopez O., Blanco C., Keyes K., et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 2008, 65(7):805-815.
17. Forman D.N., Videbech P., Hedegaard M., et al. Postpartum depression: identification of women at risk. BJOG 2000, 107(10):1210-1217.
18. Gaynes B.N., Gavin N., Meltzer-Brody S., et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) 2005, 119:1-8.
19. Marcus S.M. Depression during pregnancy: rates, risks and consequences-Motherisk Update 2008. Can J Clin Pharmacol 2009, 16(1):e15-e22.
20. Andersson L., Sundstrom-Poromaa I., Bixo M., et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003, 189(1):148-154.
21. Larsson C., Sydsjo G., Josefsson A. Health, sociodemographic data, and pregnancy outcome in women with antepartum depressive symptoms. Obstet Gynecol 2004, 104(3):459-466.
22. Chung T.K., Lau T.K., Yip A.S., et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001, 63(5):830-834.
23. Wisner K.L., Sit D.K., Hanusa B.H., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166(5):557-566.
24. Dayan J., Creveuil C., Herlicoviez M., et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002, 155(4):293-301.
25. Robertson E., Grace S., Wallington T., et al. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry 2004, 26(4):289-295.
26. Kumar R., Robson K.M. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984, 144:35-47.
27. Kendell R.E., McGuire R.J., Connor Y., et al. Mood changes in the first three weeks after childbirth. J Affect Disord 1981, 3(4):317-326.
28. Wisner K.L., Peindl K., Hanusa B.H. Relationship of psychiatric illness to childbearing status: a hospital-based epidemiologic study. J Affect Disord 1993, 28(1):39-50.
29. Vik T., Grote V., Escribano J., et al. Infantile colic, prolonged crying and maternal postnatal depression. Acta Paediatr 2009, 98(8):1344-1348.
30. McMahon C.A., Barnett B., Kowalenko N.M., et al. Maternal attachment state of mind moderates the impact of postnatal depression on infant attachment. J Child Psychol Psychiatry 2006, 47(7):660-669.
31. Brennan P.A., Pargas R., Walker E.F., et al. Maternal depression and infant cortisol: influences of timing, comorbidity and treatment. J Child Psychol Psychiatry 2008, 49(10):1099-1107.
32. Laplante D.P., Barr R.G., Brunet A., et al. Stress during pregnancy affects general intellectual and language functioning in human toddlers. Pediatr Res 2004, 56(3):400-410.
33. Murray L., Cooper P. Effects of postnatal depression on infant development. Arch Dis Child 1997, 77(2):99-101.
34. Dawson G.A.S. On the origins of a vulnerability to depression: the influence of the early social environment on the development of psychobiological systems related to risk of affective disorder. Minnesota Symposia on Child Psychology: the effects of early adversity on neurobehavioral development 2000, vol. 31:245-279. Lawrence Erlbaum Associates, Mahwah (NJ). C.A. Nelson (Ed.).
35. Yonkers K.A., Wisner K.L., Stewart D.E., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009, 31:403-413.
36. Soares C.N., Cohen L.S. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J 2001, 119(2):78-83.
37. Bromberger J.T., Assmann S.F., Avis N.E., et al. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol 2003, 158(4):347-356.
38. Cohen L.S., Soares C.N., Vitonis A.F., et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006, 63(4):385-390.
39. Freeman E.W., Sammel M.D., Lin H., et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006, 63(4):375-382.
40. Schmidt P.J., Nieman L., Danaceau M.A., et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000, 183(2):414-420.
41. Carranza-Lira S., Valentino-Figueroa M.L. Estrogen therapy for depression in postmenopausal women. Int J Gynaecol Obstet 1999, 65(1):35-38.
42. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
43. Hersh A.L., Stefanick M.L., Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004, 291(1):47-53.
44. McIntyre R.S., Konarski J.Z., Grigoriadis S., et al. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 2005, 172(1):57-59.
45. Soares C.N. Practical strategies for diagnosing and treating depression in women: menopausal transition. J Clin Psychiatry 2008, 69(10):e30.
46. Pirotta M.V., Cohen M.M., Kotsirilos V., et al. Complementary therapies: have they become accepted in general practice?. Med J Aust 2000, 172(3):105-109.
47. Barnes P.M., Bloom B., Nahin R.L. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2009, 12:1-23.
48. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998, 280(18):1569-1575.
49. Tindle H.A., Davis R.B., Phillips R.S., et al. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005, 11(1):42-49.
50. Mackenzie E.R., Taylor L., Bloom B.S., et al. Ethnic minority use of complementary and alternative medicine (CAM): a national probability survey of CAM utilizers. Altern Ther Health Med 2003, 9(4):50-56.
51. Weissman M.M., Leaf P.J., Holzer C.E., et al. The epidemiology of depression. An update on sex differences in rates. J Affect Disord 1984, 7(3-4):179-188.
52. Wu P., Fuller C., Liu X., et al. Use of complementary and alternative medicine among women with depression: results of a national survey. Psychiatr Serv 2007, 58(3):349-356.
53. Elkins G., Rajab M.H., Marcus J. Complementary and alternative medicine use by psychiatric inpatients. Psychol Rep 2005, 96(1):163-166.
54. Unutzer J., Klap R., Sturm R., et al. Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 2000, 157(11):1851-1857.
55. Mischoulon D., Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002, 76(5):1158S-1161S.
56. Spillmann M., Fava M. S-adenosyl-methione (ademthionine) in psychiatric disorders. CNS Drugs 1996, 6:416-425.
57. Hardy M., Coulter I., Morton S.C., et al. S-Adenosyl-L-methionine (SAMe) for depression, osteoarthritis and liver disease 2002, Agency for Healthcare Research and Quality, Rockville (MD).
58. Delle Chiaie R., Pancheri P., Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002, 76(5):1172S-1176S.
59. Bressa G.M. S-Adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994, 154:7-14.
60. Pancheri P., Scapicchio P., Chiaie R.D. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol 2002, 5(4):287-294.
61. Thachil A.F., Mohan R., Bhugra D. The evidence base of complementary and alternative therapies in depression. J Affect Disord 2007, 97(1-3):23-35.
62. Alpert J.E., Papakostas G., Mischoulon D., et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004, 24(6):661-664.
63. Goren J.L., Stoll A.L., Damico K.E., et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004, 24(11):1501-1507.
64. Carney M.W., Chary T.K., Bottiglieri T., et al. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry 1987, 150:724-725.
65. Cerutti R., Sichel M.P., Perin M., et al. Psychological distress during the puerperium: a novel therapeutic approach using S-adenosylmethionine. Curr Ther Res 1993, 53(6):701-716.
66. Cozens D.O., Barton S.J., Clark R., et al. Reproductive toxicity studies of ademetionine. Arzneimittelforschung 1988, 38:1625-1629.
67. Salmaggi P., Bressa G.M., Nicchia G., et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993, 59(1):34-40.
68. Papakostas G.I., Petersen T., Mischoulon D., et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004, 65(8):1090-1095.
69. Bottiglieri T., Laundy M., Crellin R., et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000, 69(2):228-232.
70. Gilbody S., Lewis S., Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol 2007, 165(1):1-13.
71. Lopez-Leon S., Janssens A.C., Gonzalez-Zuloeta Ladd A.M., et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 2008, 13(8):772-785.
72. Papakostas G.I., Petersen T., Mischoulon D., et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004, 65(8):1096-1098.
73. Alpert M., Silva R.R., Pouget E.R. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003, 23(3):309-313.
74. Coppen A., Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000, 60(2):121-130.
75. Miyake Y., Sasaki S., Tanaka K., et al. Dietary folate and vitamins B12, B6, and B2 intake and the risk of postpartum depression in Japan: the Osaka Maternal and Child Health Study. J Affect Disord 2006, 96(1-2):133-138.
76. Su K.P., Huang S.Y., Chiu C.C., et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003, 13(4):267-271.
77. Nemets B., Stahl Z., Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002, 159(3):477-479.
78. Marangell L.B., Martinez J.M., Zboyan H.A., et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003, 160(5):996-998.
79. Mischoulon D., Papakostas G., Dording C.M., et al. A double-blind randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009, 70(12):1636-1644.
80. Parker G., Gibson N.A., Brotchie H., et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006, 163(6):969-978.
81. Kris-Etherton P.M., Harris W.S., Appel L.J. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003, 23(2):151-152.
82. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 2006, 113(1):31-35.
83. McGregor J.A., Allen K.G., Harris M.A., et al. The omega-3 story: nutritional prevention of preterm birth and other adverse pregnancy outcomes. Obstet Gynecol Surv 2001, 56(5 Suppl 1):S1-13.
84. Freeman M.P. Omega-3 fatty acids and perinatal depression: a review of the literature and recommendations for future research. Prostaglandins Leukot Essent Fatty Acids 2006, 75(4-5):291-297.
85. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67(12):1954-1967.
86. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. Eur J Clin Nutr 1995, 49(7):508-516.
87. Harel Z., Biro F.M., Kottenhahn R.K., et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996, 174(4):1335-1338.
88. Puolakka J., Makarainen L., Viinikka L., et al. Biochemical and clinical effects of treating the premenstrual syndrome with prostaglandin synthesis precursors. J Reprod Med 1985, 30(3):149-153.
89. Callender K., Thomas C.S. Treating the premenstrual syndrome. BMJ 1988, 297(6649):684.
90. Collins A., Cerin A., Coleman G., et al. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 1993, 81(1):93-98.
91. Khoo S.K., Munro C., Battistutta D. Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 1990, 153(4):189-192.
92. Dunstan J.A., Simmer K., Dixon G., et al. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2008, 93(1):F45-F50.
93. Hibbeln J.R., Davis J.M., Steer C., et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 2007, 369(9561):578-585.
94. Levant B., Radel J.D., Carlson S.E. Reduced brain DHA content after a single reproductive cycle in female rats fed a diet deficient in N-3 polyunsaturated fatty acids. Biol Psychiatry 2006, 60(9):987-990.
95. Oken E., Kleinman K.P., Berland W.E., et al. Decline in fish consumption among pregnant women after a national mercury advisory. Obstet Gynecol 2003, 102(2):346-351.
96. Benisek D., Shabert J., Skornick R. Dietary intake of polyunsaturated fatty acids by pregnant or lactating women in the United States. Obstet Gynecol 2000, 95:7778.
97. Hibbeln J.R. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord 2002, 69(1-3):15-29.
98. Golding J., Steer C., Emmett P., et al. High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology 2009, 20(4):598-603.
99. Browne J.C., Scott K.M., Silvers K.M. Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. J Affect Disord 2006, 90(2-3):131-139.
100. Miyake Y., Sasaki S., Yokoyama T., et al. Risk of postpartum depression in relation to dietary fish and fat intake in Japan: the Osaka Maternal and Child Health Study. Psychol Med 2006, 36(12):1727-1735.
101. Strom M., Mortensen E.L., Halldorsson T.I., et al. Fish and long-chain n-3 polyunsaturated fatty acid intakes during pregnancy and risk of postpartum depression: a prospective study based on a large national birth cohort. Am J Clin Nutr 2009, 90(1):149-155.
102. Rees A.M., Austin M.P., Owen C., et al. Omega-3 deficiency associated with perinatal depression: case control study. Psychiatry Res 2009, 166(2-3):254-259.
103. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. An open trial of omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatr 2006, 18:21-24.
104. Rees A.M., Austin M.P., Parker G.B. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 2008, 42(3):199-205.
105. Freeman M.P., Davis M., Sinha P., et al. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008, 110(1-2):142-148.
106. Su K.P., Huang S.Y., Chiu T.H., et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69(4):644-651.
107. Freeman M.P., Sinha P. Tolerability of omega-3 fatty acid supplements in perinatal women. Prostaglandins Leukot Essent Fatty Acids 2007, 77(3-4):203-208.
108. Foran S.E., Flood J.G., Lewandrowski K.B. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish?. Arch Pathol Lab Med 2003, 127(12):1603-1605.
109. Newton K.M., Reed S.D., LaCroix A.Z., et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006, 145(12):869-879.
110. Lucas M., Asselin G., Merette C., et al. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 2009, 16(2):357-366.
111. Terman M., Terman J.S., Quitkin F.M., et al. Light therapy for seasonal affective disorder. A review of efficacy. Neuropsychopharmacology 1989, 2(1):1-22.
112. Eastman C.I., Young M.A., Fogg L.F., et al. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 1998, 55(10):883-889.
113. Kripke D.F., Mullaney D.J., Klauber M.R., et al. Controlled trial of bright light for nonseasonal major depressive disorders. Biol Psychiatry 1992, 31(2):119-134.
114. Sumaya I.C., Rienzi B.M., Deegan J.F., et al. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. J Gerontol A Biol Sci Med Sci 2001, 56(6):M356-M360.
115. Golden R.N., Gaynes B.N., Ekstrom R.D., et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005, 162(4):656-662.
116. Sit D., Wisner K.L., Hanusa B.H., et al. Light therapy for bipolar disorder: a case series in women. Bipolar Disord 2007, 9(8):918-927.
117. Chan P.K., Lam R.W., Perry K.F. Mania precipitated by light therapy for patients with SAD. J Clin Psychiatry 1994, 55(10):454.
118. Parry B.L., Newton R.P. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 2001, 25(Suppl 5):S102-S108.
119. Parry B.L., Mahan A.M., Mostofi N., et al. Light therapy of late luteal phase dysphoric disorder: an extended study. Am J Psychiatry 1993, 150(9):1417-1419.
120. Lam R.W., Carter D., Misri S., et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999, 86(3):185-192.
121. Oren D.A., Wisner K.L., Spinelli M., et al. An open trial of morning light therapy for treatment of antepartum depression. Am J Psychiatry 2002, 159(4):666-669.
122. Epperson C.N., Terman M., Terman J.S., et al. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J Clin Psychiatry 2004, 65(3):421-425.
123. Corral M., Wardrop A.A., Zhang H., et al. Morning light therapy for postpartum depression. Arch Womens Ment Health 2007, 10(5):221-224.
124. Trivedi M.H., Greer T.L., Grannemann B.D., et al. Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract 2006, 12(4):205-213.
125. Otto M.W., Church T.S., Craft L.L., et al. Exercise for mood and anxiety disorders. J Clin Psychiatry 2007, 68(5):669-676.
126. Strawbridge W.J., Deleger S., Roberts R.E., et al. Physical activity reduces the risk of subsequent depression for older adults. Am J Epidemiol 2002, 156(4):328-334.
127. Penninx B.W., Rejeski W.J., Pandya J., et al. Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci 2002, 57(2):P124-P132.
128. Dunn A.L., Trivedi M.H., Kampert J.B., et al. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005, 28(1):1-8.
129. Prior J.C., Vigna Y., Alojada N. Conditioning exercise decreases premenstrual symptoms. A prospective controlled three month trial. Eur J Appl Physiol Occup Physiol 1986, 55(4):349-355.
130. Prior J.C., Vigna Y., Sciarretta D., et al. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril 1987, 47(3):402-408.
131. Steege J.F., Blumenthal J.A. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993, 37(2):127-133.
132. Stoddard J.L., Dent C.W., Shames L., et al. Exercise training effects on premenstrual distress and ovarian steroid hormones. Eur J Appl Physiol 2007, 99(1):27-37.
133. Artal R., O'Toole M. Guidelines of the American College of Obstetricians and Gynecologists for exercise during pregnancy and the postpartum period. Br J Sports Med 2003, 37(1):6-12. [discussion: 12].
134. Da Costa D., Rippen N., Dritsa M., et al. Self-reported leisure-time physical activity during pregnancy and relationship to psychological well-being. J Psychosom Obstet Gynaecol 2003, 24(2):111-119.
135. Heh S.S., Huang L.H., Ho S.M., et al. Effectiveness of an exercise support program in reducing the severity of postnatal depression in Taiwanese women. Birth 2008, 35(1):60-65.
136. Butterweck V. Mechanism of action of St John's wort in depression: what is known?. CNS Drugs 2003, 17(8):539-562.
137. Simmen U., Burkard W., Berger K., et al. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 1999, 19(1-4):59-74.
138. Simmen U., Higelin J., Berger-Buter K., et al. Neurochemical studies with St. John's wort in vitro. Pharmacopsychiatry 2001, 34(Suppl 1):S137-S142.
139. Gobbi M., Moia M., Pirona L., et al. In vitro binding studies with two Hypericum perforatum extracts-hyperforin, hypericin and biapigenin-on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001, 34(Suppl 1):S45-S48.
140. Cott J.M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997, 30(Suppl 2):108-112.
141. Linde K., Mulrow C.D., Berner M., et al. St John's wort for depression. Cochrane Database Syst Rev 2005, (2). CD000448.
142. Roder C., Schaefer M., Leucht S. Fortschr Neurol Psychiatr 2004, 72(6):330-343. [in German].
143. Hennessy M., Kelleher D., Spiers J.P., et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002, 53(1):75-82.
144. Gutmann H., Poller B., Buter K.B., et al. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?. Planta Med 2006, 72(8):685-690.
145. Roby C.A., Anderson G.D., Kantor E., et al. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000, 67(5):451-457.
146. Murphy P.A., Kern S.E., Stanczyk F.Z., et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005, 71(6):402-408.
147. Schwarz U.I., Buschel B., Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003, 55(1):112-113.
148. Borges L.V., do Carmo Cancino J.C., Peters V.M., et al. Development of pregnancy in rats treated with Hypericum perforatum. Phytother Res 2005, 19(10):885-887.
149. Rayburn W.F., Christensen H.D., Gonzalez C.L. Effect of antenatal exposure to Saint John's wort (Hypericum) on neurobehavior of developing mice. Am J Obstet Gynecol 2000, 183(5):1225-1231.
150. Rayburn W.F., Gonzalez C.L., Christensen H.D., et al. Impact of hypericum (St.-John's-wort) given prenatally on cognition of mice offspring. Neurotoxicol Teratol 2001, 23(6):629-637.
151. Rayburn W.F., Gonzalez C.L., Christensen H.D., et al. Effect of prenatally administered hypericum (St John's wort) on growth and physical maturation of mouse offspring. Am J Obstet Gynecol 2001, 184(2):191-195.
152. Dugoua J.J., Mills E., Perri D., et al. Safety and efficacy of St. John's wort (hypericum) during pregnancy and lactation. Can J Clin Pharmacol 2006, 13(3):e268-e276.
153. Chan L.Y., Chiu P.Y., Lau T.K. A study of hypericin-induced teratogenicity during organogenesis using a whole rat embryo culture model. Fertil Steril 2001, 76(5):1073-1074.
154. Gregoretti B., Stebel M., Candussio L., et al. Toxicity of Hypericum perforatum (St. John's wort) administered during pregnancy and lactation in rats. Toxicol Appl Pharmacol 2004, 200(3):201-205.
155. Moretti M.E., Maxson A., Hanna F., et al. Evaluating the safety of St. John's Wort in human pregnancy. Reprod Toxicol 2009, 28(1):96-99.
156. Klier C.M., Schafer M.R., Schmid-Siegel B., et al. St. John's wort (Hypericum perforatum)-is it safe during breastfeeding?. Pharmacopsychiatry 2002, 35(1):29-30.
157. Klier C.M., Schmid-Siegel B., Schafer M.R., et al. St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants. J Clin Psychiatry 2006, 67(2):305-309.
158. Lee A., Minhas R., Matsuda N., et al. The safety of St. John's wort (Hypericum perforatum) during breastfeeding. J Clin Psychiatry 2003, 64(8):966-968.
159. van Die M.D., Burger H.G., Bone K.M., et al. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause 2009, 16(1):156-163.
160. Uebelhack R., Blohmer J.U., Graubaum H.J., et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006, 107(2 Pt 1):247-255.
161. Allen J.J., Schnyer R.N., Chambers A.S., et al. Acupuncture for depression: a randomized controlled trial. J Clin Psychiatry 2006, 67(11):1665-1673.
162. Luo H., Meng F., Jia Y., et al. Clinical research on the therapeutic effect of the electro-acupuncture treatment in patients with depression. Psychiatry Clin Neurosci 1998, 52(Suppl):S338-S340.
163. Gallagher S.M., Allen J.J., Hitt S.K., et al. Six-month depression relapse rates among women treated with acupuncture. Complement Ther Med 2001, 9(4):216-218.
164. Zhang W.J., Yang X.B., Zhong B.L. Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, sham-controlled trial. J Altern Complement Med 2009, 15(8):837-844.
165. Wang H., Qi H., Wang B.S., et al. Is acupuncture beneficial in depression: a meta-analysis of 8 randomized controlled trials?. J Affect Disord 2008, 111(2-3):125-134.
166. Halbreich U. Systematic reviews of clinical trials of acupuncture as treatment for depression: how systematic and accurate are they?. CNS Spectr 2008, 13(4):293-294. 299-300.
167. Streitberger K., Kleinhenz J. Introducing a placebo needle into acupuncture research. Lancet 1998, 352(9125):364-365.
168. Rabl M., Ahner R., Bitschnau M., et al. Acupuncture for cervical ripening and induction of labor at term-a randomized controlled trial. Wien Klin Wochenschr 2001, 113(23-24):942-946.
169. Motl J.M. Acupuncture. Handbook of complementary and alternative therapies in mental health 2002, 443-452. Academic Press, San Francisco (CA). S. Shannon (Ed.).
170. Gaudet L.M., Dyzak R., Aung S.K., et al. Effectiveness of acupuncture for the initiation of labour at term: a pilot randomized controlled trial. J Obstet Gynaecol Can 2008, 30(12):1118-1123.
171. Manber R., Schnyer R.N., Allen J.J., et al. Acupuncture: a promising treatment for depression during pregnancy. J Affect Disord 2004, 83(1):89-95.
172. Cho S.H., Whang W.W. Acupuncture for vasomotor menopausal symptoms: a systematic review. Menopause 2009, 16(5):1065-1073.
173. Borud E.K., Alraek T., White A., et al. The Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study, a randomized controlled trial. Menopause 2009, 16(3):484-493.
174. Avis N.E., Legault C., Coeytaux R.R., et al. A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes. Menopause 2008, 15(6):1070-1078.
175. Nir Y., Huang M.I., Schnyer R., et al. Acupuncture for postmenopausal hot flashes. Maturitas 2007, 56(4):383-395.
176. Cohen S.M., Rousseau M.E., Carey B.L. Can acupuncture ease the symptoms of menopause?. Holist Nurs Pract 2003, 17(6):295-299.
177. Huang M.I., Nir Y., Chen B., et al. A randomized controlled pilot study of acupuncture for postmenopausal hot flashes: effect on nocturnal hot flashes and sleep quality. Fertil Steril 2006, 86(3):700-710.
178. Vincent A., Barton D.L., Mandrekar J.N., et al. Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause 2007, 14(1):45-52.
179. Sandberg M., Wijma K., Wyon Y., et al. Effects of electro-acupuncture on psychological distress in postmenopausal women. Complement Ther Med 2002, 10(3):161-169.
180. Barnes P, Powell-Griner E, McFann K, et al. CDC advance data report #343. Complementary and alternative medicine use among adults: United States, 2002; 2004.
181. Barnes PM, Bloom B, Nahin R. CDC national health statistics report #12. Complementary and alternative medicine use among adults and children: United States, 2007; 2008.